A molecule’s ‘handedness’ can determine whether it’s an effective drug – 4 examples of pharmaceuticals where chirality matters

The 2026 Nobel Prize in chemistry recognized Henri Kagan and Kenso Soai for their groundbreaking work on chirality - the "handedness" of molecules that can dramatically impact their effectiveness as pharmaceuticals. Chiral molecules have mirror images that cannot be superimposed on one another, a property found throughout nature from galaxies to snails.

When chemists synthesize chiral molecules without any external chiral agents, they produce a 50/50 mixture of both mirror forms, known as a racemic mixture. This raises the question of how life on Earth evolved to be predominantly one-handed - a phenomenon called homochirality.

Kagan's work in the 1980s demonstrated that catalysts, which speed up chemical reactions, do not need to be completely symmetric to produce a pure one-handed product. In some cases, even a partially chiral catalyst could yield a product purer than the catalyst itself. Soai's research in the 1990s revealed a molecule capable of copying itself and favoring its own handedness. By starting with a 51:49 imbalance, this molecule amplified the imbalance to over 99.5% after several reaction cycles.

The implications of chirality in medicine are profound. Since humans evolved under homochirality, our bodies contain highly chiral proteins and enzymes. When a drug is administered as a racemic mixture, one mirror image may perfectly fit a receptor, while the other may be inactive or even cause side effects. Controlling chirality has been crucial for successful drug development.

For example, thalidomide, prescribed in the late 1950s to treat insomnia and morning sickness, caused severe birth defects when taken in equal proportions of its two mirror forms. Ibuprofen, a widely used pain reliever, relies on its S-form to block pain signals, while its inactive R-form is largely discarded by the body.